^
    7d
    INCA036873-101: A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (2025-523130-11-00)
    P1, N=150, Not yet recruiting, Incyte Corp.
    New P1 trial
    13d
    Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=37, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Welireg (belzutifan)
    15d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    1m
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    1m
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, OncoVerity, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    2ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Completed --> Active, not recruiting
    Enrollment closed
    |
    azacitidine • cusatuzumab (ARGX-110)
    2ms
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Recruiting, OncoVerity, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    3ms
    Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    3ms
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, OncoVerity, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    3ms
    CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target. (PubMed, Leukemia)
    Furthermore, the ADCC-enhanced anti-CD70 antibody, cusatuzumab, demonstrated high efficacy in treating myeloma in xenotransplantation models. Collectively, these findings underscore the critical role of CD70/CD27 signaling in activating MAPK/ERK and Wnt pathways essential for MM progression. Targeting CD70 with blocking or ADCC-enhanced antibodies represents a promising therapeutic strategy, particularly for advanced MM stages characterized by high CD70 expression.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
    |
    cusatuzumab (ARGX-110)
    3ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Completed, OncoVerity, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    azacitidine • cusatuzumab (ARGX-110)
    4ms
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV